Premium
Impact of hypoalbuminemia on the prognosis of relapsed/refractory B‐cell lymphoma treated with axicabtagene ciloleucel
Author(s) -
Melody Megan,
Gandhi Sangeetha,
Rahman Zaid Abdel,
LengerkeDiaz Paula,
Gan Nicole,
Rosenthal Allison,
Truong Tuan,
Novo Mattia,
Brandes Eva,
Lange Gina,
Estby Breana,
Johnston Patrick,
Ansell Steve,
Bennani N. Nora,
Paludo Jonas,
Bisneto Jose Villasboas,
Ayala Ernesto,
Tun Han W.,
Murthy Hemant S.,
Roy Vivek,
Foran James,
Castro Januario,
Lin Yi,
KharfanDabaja Mohamed A.
Publication year - 2021
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13609
Subject(s) - hypoalbuminemia , medicine , gastroenterology , adverse effect , refractory (planetary science) , lymphoma , albumin , oncology , astrobiology , physics
Hypoalbuminemia is a known adverse prognostic factor in lymphomas. Yet, it is unknown if axicabtagene ciloleucel (axi‐cel) overcomes the adverse prognostic impact of hypoalbuminemia in relapsed/refractory large B‐cell lymphoma. Methods We conducted a retrospective analysis across three Mayo Clinic centers to assess the relationship of hypoalbuminemia (defined as a serum albumin (SA) levels ≤ 3.5 g/dL) on outcomes of patients treated with axi‐cel. Results This analysis included 81 patients. Two patients had no available SA levels preceding axi‐cel infusion. Eighteen patients (22.8%) had hypoalbuminemia with a median SA of 3.3 g/dL. Patients with normal SA had a statistically higher ORR than those without hypoalbuminemia ( P = .018). There was no difference in 1‐year PFS and OS between the group with hypoalbuminemia and the group with normal SA levels (48% vs 49%, P = .81) and (74% vs 73%, P = .97), respectively. There was no difference in the severity or median duration of cytokine release syndrome or neurotoxicity between the two groups. Conclusion Notwithstanding the limitations related to the relatively small sample size, axi‐cel therapy appears to overcome the adverse effect of hypoalbuminemia on OS and PFS. Large multicenter clinical studies are certainly needed to validate these findings.